MedTrace Logo

Levetiracetam in Central Pain in Multiple Sclerosis(MS)

NCT00423527 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-12-18

No results posted yet for this study

Summary

Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.

Conditions

Interventions

DRUG

levetiracetam

Levetiracetam tablets 500 mg, total daily dose 3000 mg

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Søren H Sindrup, MD · Department of Neurology, Odense Unviersity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423527 on ClinicalTrials.gov